March 1, 2013—The Office of Pharmacy Affairs (OPA) and Apexus/340B Prime Vendor Program (PVP) have each issued lengthy FAQs fleshing out OPA’s new interpretation of the 340B statute’s “GPO prohibition.”
The 340B law prohibits disproportionate share (DSH), children’s, and free-standing cancer hospitals from participating in group purchasing organizations for 340B drugs, which are for outpatients only.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)